# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome</td>
<td>2</td>
</tr>
<tr>
<td>About MDS</td>
<td>3</td>
</tr>
<tr>
<td>Purpose, Mission and Goals</td>
<td>3</td>
</tr>
<tr>
<td>MDS Officers (2019-2021)</td>
<td>3</td>
</tr>
<tr>
<td>MDS International Executive Committee</td>
<td>4</td>
</tr>
<tr>
<td>MDS Virtual Congress 2020 Task Force</td>
<td>4</td>
</tr>
<tr>
<td>Congress Scientific Program Committee</td>
<td>4</td>
</tr>
<tr>
<td>Congress Local Organizing Committee</td>
<td>4</td>
</tr>
<tr>
<td>Past-Presidents</td>
<td>4</td>
</tr>
<tr>
<td>International Medical Society for Motor Disturbances Past-Presidents</td>
<td>4</td>
</tr>
<tr>
<td>MDS International Secretariat</td>
<td>4</td>
</tr>
<tr>
<td>Virtual Congress Information</td>
<td>5</td>
</tr>
<tr>
<td>Abstract Poster Information</td>
<td>5</td>
</tr>
<tr>
<td>Exhibition</td>
<td>5</td>
</tr>
<tr>
<td>Official Language</td>
<td>5</td>
</tr>
<tr>
<td>Registration</td>
<td>5</td>
</tr>
<tr>
<td>Virtual Congress Events</td>
<td>6</td>
</tr>
<tr>
<td>CME Information</td>
<td>6</td>
</tr>
<tr>
<td>Daily Schedule</td>
<td>7</td>
</tr>
<tr>
<td>Schedule-at-a-Glance</td>
<td>7</td>
</tr>
<tr>
<td>Virtual Congress Session Definitions</td>
<td>8</td>
</tr>
<tr>
<td>Friday, September 11, 2020</td>
<td>9</td>
</tr>
<tr>
<td>Saturday, September 12, 2020</td>
<td>9</td>
</tr>
<tr>
<td>Sunday, September 13, 2020</td>
<td>10</td>
</tr>
<tr>
<td>Monday, September 14, 2020</td>
<td>16</td>
</tr>
<tr>
<td>Tuesday, September 15, 2020</td>
<td>20</td>
</tr>
<tr>
<td>Wednesday, September 16, 2020</td>
<td>24</td>
</tr>
<tr>
<td>Non-CME Educational Activities</td>
<td>26</td>
</tr>
<tr>
<td>Faculty Listing</td>
<td>27</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>30</td>
</tr>
<tr>
<td>Membership Information</td>
<td>32</td>
</tr>
</tbody>
</table>
Dear Colleagues,

We are excited to share this MDS Virtual Congress with you. In this first ever virtual congress on movement disorders, you can expect over 30 hours of educational content through our virtual platform, including plenary sessions, teaching courses and access to the accepted abstracts.

The Society made the difficult decision to replace the in-person meeting in Philadelphia with a virtual meeting, and by doing so, is rising to the occasion after the COVID-19 crisis in order to fulfill its mission. This meeting will be open to healthcare professionals across the globe and will allow delegates an opportunity to access the full International Congress Scientific Program content through a virtual platform without concern for health, welfare or travel.

The MDS Virtual Congress 2020 scientific sessions, sponsored symposia, virtual exhibits, and poster sessions will be available on demand for free until October 1, 2020 for those participants who have registered by September 16, 2020. After October 1, 2020 the Virtual Congress will continue to be available on demand for MDS Members for a limited time.

Although we will not meet together in Philadelphia this September, I am proud to see the MDS community come together virtually to achieve our mission.

Claudia Trenkwalder
President, International Parkinson and Movement Disorder Society, 2019-2021
ABOUT MDS

The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control.

PURPOSE, MISSION AND GOALS

Purpose:
The objective and mission of the Society shall be to advance the neurological sciences pertaining to Movement Disorders; to improve the diagnosis and treatment of patients; to operate exclusively for scientific, scholarly and educational purposes; to encourage research; to provide forums, such as medical journals, scientific symposia and International Congresses, for sharing ideas and for advancing the related clinical and scientific disciplines; to encourage interest and participation in the activities of the Society among healthcare and allied professionals and scientists; and to collaborate with other related professional and lay organizations.

Mission and Goals:
To disseminate knowledge about Movement Disorders by:
• Providing educational programs for clinicians, scientists and the general public designed to advance scientific and clinical knowledge about Movement Disorders
• Sponsoring International Congresses and Symposia on Movement Disorders
• Collaborating with other international organizations and lay groups
• Publishing journals, videotapes and other collateral materials committed to high scientific standards and peer review

To promote research into causes, prevention and treatment of Movement Disorders by:
• Using the Society’s influence and resources to enhance support for research
• Facilitating the dissemination of information about research
• Encouraging the training of basic and clinical scientists in Movement Disorders and related disorders

For the purposes of favorably affecting the care of patients with Movement Disorders, the Society will provide expertise, advice and guidance to:
• Regulatory agencies to assist them in the approval process of safe and effective therapeutic interventions
• The public (media) and patient support groups by informing them of new research and therapeutic advances
• Governments to assist them in the development of policies that affect support of research and patient care
• Educational efforts to assist in developing standards of training in the specialty

MDS OFFICERS (2019-2021)

President
Claudia Trenkwalder
Germany

President-Elect
Francisco Cardoso
Brazil

Secretary
Bastiaan Bloem
Netherlands

Secretary-Elect
Charles Adler
USA

Treasurer
Louis CS Tan
Singapore

Treasurer-Elect
Irene Litvan
USA

Past-President
Christopher Goetz
USA

ABOUT MDS
ABOUT MDS

MDS INTERNATIONAL EXECUTIVE COMMITTEE
Shengdi Chen
Mark Edwards
Cristian Falup-Pecurariu
Joaquim Ferreira
Marina de Koning-Tijssen
Alice Nieuwboer
D. James Surmeier
Pille Taba
Mayela Rodriguez-Violante
Ruey-Meei Wu

MDS INTERNATIONAL SECRETARIAT
International Parkinson and Movement Disorder Society
555 East Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA
Tel: +1 414-276-2145
Fax: +1 414-276-3349
Email: info@movementdisorders.org
Website: www.movementdisorders.org

MDS VIRTUAL CONGRESS 2020 TASK FORCE
Chairs: Vincenzo Bonifati, Netherlands
Chairs: Oscar Gershanik, Argentina
Chairs: Claudia Trenkwalder, Germany
Francisco Cardoso, Brazil
Margherita Fabbrì, Italy
Hyder Jinnah, USA
Andrew Siderowf, USA
Matthew Stern, USA
Louis Tan, Singapore

CONGRESS LOCAL ORGANIZING COMMITTEE
Chair: Matthew Stern, USA
Co-Chair: Andrew Siderowf, USA
Nabila Dahodwala, USA
Andres Deik, USA
Jill Farmer, USA
Pedro Gonzalez-Alegre, USA
Dan Kremens, USA
Tsao-Wei Liang, USA
Meredith Spindler, USA
Dan Weintraub, USA
Allison Willis, USA

CONGRESS SCIENTIFIC PROGRAM COMMITTEE
Chair: Vincenzo Bonifati, Netherlands
Co-Chair: Andrew Siderowf, USA
Orlando Barsottini, Brazil
Roongroj Bhidayasiri, Thailand
Per Borghammer, Denmark
Francisco Cardoso, Brazil
Pietro Cortelli, Italy
Alberto Espay, USA
Jennifer Friedman, USA
Jennifer Goldman, USA
Etienne Hirsch, France
Beomseok Jeon, South Korea
Andrea Kühn, Germany
Shen-Yang Lim, Malaysia
Karen Marder, USA
Wassilios Meissner, France
Tiago Outeiro, Germany
Maria Stamelou, Greece
Carolyn Sue, Australia
Ryosuke Takahashi, Japan
Claudia Trenkwalder, Germany
Ad-Hoc Member: Terry Ellis, USA
Ad-Hoc Member: Oscar Gershanik, Argentina
Ad-Hoc Member: Hyder Jinnah, USA
Ad-Hoc Member: Ron Postuma, Canada
Ad-Hoc Member: Veronica Santini, USA

PAST-PRESIDENTS
2017-2019 Christopher Goetz, USA
2015-2017 Oscar Gershanik, Argentina
2013-2015 Matthew Stern, USA
2011-2013 Günther Deuschl, Germany
2009-2011 Philip Thompson, Australia
2007-2009 Anthony Lang, Canada
2005-2006 Andrew Lees, United Kingdom
2003-2004 C. Warren Olanow, USA
2001-2002 Werner Poewe, Austria
1999-2000 Mark Hallett, USA
1997-1998 Eduardo Tolosa, Spain
1995-1996 Joseph Jankovic, USA
1991-1994 C. David Marsden, United Kingdom
1988-1991 Stanley Fahn, USA

INTERNATIONAL MEDICAL SOCIETY FOR MOTOR DISTURBANCES PAST-PRESIDENTS
1993-1994 C. Warren Olanow, USA
1991-1992 Bastian Conrad, Germany
1989-1990 Mark Hallett, USA
1987-1988 Mario Manfredi, Italy
1985-1986 C. David Marsden, United Kingdom

MDS INTERNATIONAL EXECUTIVE COMMITTEE
Chairs: Vincenzo Bonifati, Netherlands
Chairs: Oscar Gershanik, Argentina
Chairs: Claudia Trenkwalder, Germany
Francisco Cardoso, Brazil
Margherita Fabbrì, Italy
Hyder Jinnah, USA
Andrew Siderowf, USA
Matthew Stern, USA
Louis Tan, Singapore

MDS VIRTUAL CONGRESS 2020 TASK FORCE
Chairs: Vincenzo Bonifati, Netherlands
Chairs: Oscar Gershanik, Argentina
Chairs: Claudia Trenkwalder, Germany
Francisco Cardoso, Brazil
Margherita Fabbrì, Italy
Hyder Jinnah, USA
Andrew Siderowf, USA
Matthew Stern, USA
Louis Tan, Singapore

CONGRESS LOCAL ORGANIZING COMMITTEE
Chair: Matthew Stern, USA
Co-Chair: Andrew Siderowf, USA
Nabila Dahodwala, USA
Andres Deik, USA
Jill Farmer, USA
Pedro Gonzalez-Alegre, USA
Dan Kremens, USA
Tsao-Wei Liang, USA
Meredith Spindler, USA
Dan Weintraub, USA
Allison Willis, USA

CONGRESS SCIENTIFIC PROGRAM COMMITTEE
Chair: Vincenzo Bonifati, Netherlands
Co-Chair: Andrew Siderowf, USA
Orlando Barsottini, Brazil
Roongroj Bhidayasiri, Thailand
Per Borghammer, Denmark
Francisco Cardoso, Brazil
Pietro Cortelli, Italy
Alberto Espay, USA
Jennifer Friedman, USA
Jennifer Goldman, USA
Etienne Hirsch, France
Beomseok Jeon, South Korea
Andrea Kühn, Germany
Shen-Yang Lim, Malaysia
Karen Marder, USA
Wassilios Meissner, France
Tiago Outeiro, Germany
Maria Stamelou, Greece
Carolyn Sue, Australia
Ryosuke Takahashi, Japan
Claudia Trenkwalder, Germany
Ad-Hoc Member: Terry Ellis, USA
Ad-Hoc Member: Oscar Gershanik, Argentina
Ad-Hoc Member: Hyder Jinnah, USA
Ad-Hoc Member: Ron Postuma, Canada
Ad-Hoc Member: Veronica Santini, USA

PAST-PRESIDENTS
2017-2019 Christopher Goetz, USA
2015-2017 Oscar Gershanik, Argentina
2013-2015 Matthew Stern, USA
2011-2013 Günther Deuschl, Germany
2009-2011 Philip Thompson, Australia
2007-2009 Anthony Lang, Canada
2005-2006 Andrew Lees, United Kingdom
2003-2004 C. Warren Olanow, USA
2001-2002 Werner Poewe, Austria
1999-2000 Mark Hallett, USA
1997-1998 Eduardo Tolosa, Spain
1995-1996 Joseph Jankovic, USA
1991-1994 C. David Marsden, United Kingdom
1988-1991 Stanley Fahn, USA

INTERNATIONAL MEDICAL SOCIETY FOR MOTOR DISTURBANCES PAST-PRESIDENTS
1993-1994 C. Warren Olanow, USA
1991-1992 Bastian Conrad, Germany
1989-1990 Mark Hallett, USA
1987-1988 Mario Manfredi, Italy
1985-1986 C. David Marsden, United Kingdom

MDS INTERNATIONAL SECRETARIAT
International Parkinson and Movement Disorder Society
555 East Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA
Tel: +1 414-276-2145
Fax: +1 414-276-3349
Email: info@movementdisorders.org
Website: www.movementdisorders.org
VIRTUAL CONGRESS INFORMATION

ABSTRACT POSTER INFORMATION
Beginning on September 11, 2020, Virtual Congress participants can view e-posters in the Virtual Poster Hall. Additionally, all abstracts will be published in the Movement Disorders journal e-supplement.

The MDS Virtual Congress 2020 will also feature sixteen virtual Guided Poster Tours which will be open to all participants.

EXHIBITION
Participants will have the opportunity to visit the Virtual Exhibit Hall beginning on September 12, 2020.

OFFICIAL LANGUAGE
The official language of the 2020 Virtual Congress is English.

REGISTRATION
Registration will open on July 27, 2020 and will be offered to participants at no charge. The MDS Virtual Congress 2020 scientific sessions, sponsored symposia, virtual exhibits, and the virtual poster hall will be available on-demand for free until October 1, 2020 for those participants who have registered by September 16, 2020. After October 1, 2020 the Virtual Congress will continue to be available on demand for MDS Members for a limited time.
WELCOME CEREMONY
Friday, September 11, 2020
Time: 15:00 - 16:00 GMT
All participants are encouraged to attend the Virtual Congress Welcome Ceremony. MDS President Claudia Trenkwalder and other MDS leaders will introduce this inaugural event and give a preview of what to expect throughout the week.

VIRTUAL CONGRESS EVENTS

WELCOME CEREMONY
Friday, September 11, 2020
Time: 15:00 - 16:00 GMT

All participants are encouraged to attend the Virtual Congress Welcome Ceremony. MDS President Claudia Trenkwalder and other MDS leaders will introduce this inaugural event and give a preview of what to expect throughout the week.

MDS VIRTUAL VIDEO CHALLENGE
Sunday, September 13, 2020
Time: 19:30 - 22:30 GMT
Monday, September 14, 2020
Time: 2:00 - 5:00 GMT
Please join Masters of Ceremony Anthony Lang and Kapil Sethi as they host world-renowned Movement Disorders experts in guiding participants through unique Movement Disorder cases. The cases will be presented by representatives from Movement Disorder Centers around the world and discussed by Movement Disorder Experts. Awards will be given for the most interesting and challenging cases. Country pride will add an enjoyable spirit of competition to this event. The goal of this session is for participants to learn from a series of unusual, very interesting patients and see how senior experts approach these types of challenging cases.

CME INFORMATION

TARGET AUDIENCE
Clinicians, researchers, post-doctoral fellows, medical residents, medical students, allied health professionals with an interest in current clinical trends and approaches for diagnosis and treatment of movement disorders.

OBJECTIVES
1. Evaluate the pharmacological and non-pharmacological management options available for Parkinson's disease and other movement disorders
2. Discuss the diagnostic approaches and tools available for Parkinson's disease and other movement disorders
3. Describe the pathogenesis and neurobiology of Parkinson's disease and other movement disorders

SATISFACTORY COMPLETION
Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Parkinson and Movement Disorder Society is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
The International Parkinson and Movement Disorder Society designates this live activity for a maximum of 28.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTENT VALIDITY STATEMENT
All recommendations involving clinical medicine in MDS activities are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the case of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendations conforms to the generally accepted standards of experimental design, data collection and analysis. Activities that promote recommendations, treatment or manners of practicing medicine not within the definition of CME or are knowing to have risks or dangers that outweigh the benefits or are knowing to be ineffective in the treatment of patients do not constitute valid CME.
## SCHEDULE-AT-A-GLANCE

| FRIDAY  
September 11 | SATURDAY  
September 12 | SUNDAY  
September 13 | MONDAY  
September 14 | TUESDAY  
September 15 | WEDNESDAY  
September 16 |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>Welcome Ceremony 15:00 - 16:00 GMT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 Therapeutic Plenary Session 12:00 - 14:00 GMT</td>
<td>Plenary Session 12:00 - 14:00 GMT</td>
<td>Plenary Session 12:00 - 14:00 GMT</td>
<td>Plenary Session 12:00 - 14:00 GMT</td>
<td>Plenary Session 12:00 - 14:00 GMT</td>
<td></td>
</tr>
<tr>
<td>2:30</td>
<td>3:00 Break 2:00 - 3:00 GMT</td>
<td>Parallel Sessions / Teaching Courses 14:30 - 16:30 GMT</td>
<td>Paralell Sessions / Teaching Courses 14:30 - 16:30 GMT</td>
<td>Science of Industry (non-CME) Session 14:30 - 16:30 GMT</td>
<td></td>
</tr>
<tr>
<td>3:00</td>
<td>3:30</td>
<td>4:00</td>
<td>4:30</td>
<td>5:00</td>
<td>5:30</td>
</tr>
<tr>
<td>3:30</td>
<td>4:00</td>
<td>4:30</td>
<td>5:00</td>
<td>5:30</td>
<td>6:00</td>
</tr>
<tr>
<td>4:00</td>
<td>4:30</td>
<td>5:00</td>
<td>5:30</td>
<td>6:00</td>
<td>6:30</td>
</tr>
<tr>
<td>4:30</td>
<td>5:00</td>
<td>5:30</td>
<td>6:00</td>
<td>6:30</td>
<td>7:00</td>
</tr>
<tr>
<td>5:00</td>
<td>5:30</td>
<td>6:00</td>
<td>6:30</td>
<td>7:00</td>
<td>7:30</td>
</tr>
<tr>
<td>5:30</td>
<td>6:00</td>
<td>6:30</td>
<td>7:00</td>
<td>7:30</td>
<td>8:00</td>
</tr>
<tr>
<td>6:00</td>
<td>6:30</td>
<td>7:00</td>
<td>7:30</td>
<td>8:00</td>
<td>8:30</td>
</tr>
<tr>
<td>6:30</td>
<td>7:00</td>
<td>7:30</td>
<td>8:00</td>
<td>8:30</td>
<td>9:00</td>
</tr>
<tr>
<td>7:00</td>
<td>7:30</td>
<td>8:00</td>
<td>8:30</td>
<td>9:00</td>
<td>9:30</td>
</tr>
<tr>
<td>7:30</td>
<td>8:00</td>
<td>8:30</td>
<td>9:00</td>
<td>9:30</td>
<td>10:00</td>
</tr>
<tr>
<td>8:00</td>
<td>8:30</td>
<td>9:00</td>
<td>9:30</td>
<td>10:00</td>
<td>10:30</td>
</tr>
<tr>
<td>8:30</td>
<td>9:00</td>
<td>9:30</td>
<td>10:00</td>
<td>10:30</td>
<td>11:00</td>
</tr>
<tr>
<td>9:00</td>
<td>9:30</td>
<td>10:00</td>
<td>10:30</td>
<td>11:00</td>
<td>11:30</td>
</tr>
<tr>
<td>9:30</td>
<td>10:00</td>
<td>10:30</td>
<td>11:00</td>
<td>11:30</td>
<td>12:00</td>
</tr>
<tr>
<td>10:00</td>
<td>10:30</td>
<td>11:00</td>
<td>11:30</td>
<td>12:00</td>
<td>12:30</td>
</tr>
<tr>
<td>10:30</td>
<td>11:00</td>
<td>11:30</td>
<td>12:00</td>
<td>12:30</td>
<td>13:00</td>
</tr>
<tr>
<td>11:00</td>
<td>11:30</td>
<td>12:00</td>
<td>12:30</td>
<td>13:00</td>
<td>13:30</td>
</tr>
<tr>
<td>11:30</td>
<td>12:00</td>
<td>12:30</td>
<td>13:00</td>
<td>13:30</td>
<td>14:00</td>
</tr>
<tr>
<td>12:00</td>
<td>12:30</td>
<td>13:00</td>
<td>13:30</td>
<td>14:00</td>
<td>14:30</td>
</tr>
<tr>
<td>12:30</td>
<td>13:00</td>
<td>13:30</td>
<td>14:00</td>
<td>14:30</td>
<td>15:00</td>
</tr>
<tr>
<td>13:00</td>
<td>13:30</td>
<td>14:00</td>
<td>14:30</td>
<td>15:00</td>
<td>15:30</td>
</tr>
<tr>
<td>13:30</td>
<td>14:00</td>
<td>14:30</td>
<td>15:00</td>
<td>15:30</td>
<td>16:00</td>
</tr>
<tr>
<td>14:00</td>
<td>14:30</td>
<td>15:00</td>
<td>15:30</td>
<td>16:00</td>
<td>16:30</td>
</tr>
<tr>
<td>14:30</td>
<td>15:00</td>
<td>15:30</td>
<td>16:00</td>
<td>16:30</td>
<td>17:00</td>
</tr>
<tr>
<td>15:00</td>
<td>15:30</td>
<td>16:00</td>
<td>16:30</td>
<td>17:00</td>
<td>17:30</td>
</tr>
<tr>
<td>15:30</td>
<td>16:00</td>
<td>16:30</td>
<td>17:00</td>
<td>17:30</td>
<td>18:00</td>
</tr>
<tr>
<td>16:00</td>
<td>16:30</td>
<td>17:00</td>
<td>17:30</td>
<td>18:00</td>
<td>18:30</td>
</tr>
<tr>
<td>16:30</td>
<td>17:00</td>
<td>17:30</td>
<td>18:00</td>
<td>18:30</td>
<td>19:00</td>
</tr>
<tr>
<td>17:00</td>
<td>17:30</td>
<td>18:00</td>
<td>18:30</td>
<td>19:00</td>
<td>19:30</td>
</tr>
<tr>
<td>17:30</td>
<td>18:00</td>
<td>18:30</td>
<td>19:00</td>
<td>19:30</td>
<td>20:00</td>
</tr>
<tr>
<td>18:00</td>
<td>18:30</td>
<td>19:00</td>
<td>19:30</td>
<td>20:00</td>
<td>20:30</td>
</tr>
<tr>
<td>18:30</td>
<td>19:00</td>
<td>19:30</td>
<td>20:00</td>
<td>20:30</td>
<td>21:00</td>
</tr>
<tr>
<td>19:00</td>
<td>19:30</td>
<td>20:00</td>
<td>20:30</td>
<td>21:00</td>
<td>21:30</td>
</tr>
<tr>
<td>19:30</td>
<td>20:00</td>
<td>20:30</td>
<td>21:00</td>
<td>21:30</td>
<td>22:00</td>
</tr>
<tr>
<td>20:00</td>
<td>20:30</td>
<td>21:00</td>
<td>21:30</td>
<td>22:00</td>
<td></td>
</tr>
</tbody>
</table>
VIRTUAL CONGRESS SESSION DEFINITIONS

CME Accredited Sessions

2020 Virtual Congress Themed Sessions: At each annual International Congress, the Congress Scientific Program Committee selects a theme that is highlighted throughout the meeting. This year’s theme, The Combined Multidisciplinary Approach to Movement Disorders, will be showcased with international experts serving as faculty. Meeting participants can elect to attend any or all of these sessions. Themed sessions are designated in the program with 🌟.

NEW in 2020: “Neuroscience Bridges” Plenary Session: In this session world-renowned neuroscientists provide overviews of their clinical or basic research, on topics of broad interest and relevance for the advancement of knowledge on the nervous system in physiology and pathology.

Controversies: This Plenary Session is designed to involve all Virtual Congress participants. Content is prepared to stimulate interest and debate among a panel of experts. Views from several angles will be addressed as discussion of pre-selected “hot” topics will be open for debate among the panelists.

“Highlights for 2020: Looking Towards 2021” Plenary Session: In this session MDS experts present compilations of the hottest clinical and basic research articles published in the past year in the whole field of the Movement Disorders, and expected to impact heavily on the future research.

Parallel Sessions: These concurrent sessions provide an in-depth summary of new clinical and basic research findings, state-of-the-art treatment options, and future strategies on a variety of focused topics within the field of Movement Disorders.

Plenary Sessions: These sessions provide an overview of the latest clinical and basic science research findings and state-of-the-art information relating to topics of broad interest within the field of Movement Disorders.

Skills Workshops: These concurrent sessions provide practical illustrations of clinical or scientific techniques relevant to the field of Movement Disorders through video examples and equipment demonstrations.

Special Topics in Movement Disorders: These interactive sessions address “hot” topics in science or medicine using a variety of different formats that may include lectures, video presentations, and audience interaction.

Teaching Courses: These educational programs provide up-to-date information focused on a single topic. The sessions highlight both the clinical and basic science of topics of relevance to Movement Disorder specialists. The sessions are unique in providing a syllabus that includes a review of the topic and the presentation slides.

Therapeutic Plenary Sessions: These sessions provide an overview of the latest, state-of-the-art treatment options in the diagnosis and management of Parkinson’s disease and other movement disorders.

Video Sessions: These concurrent sessions focus on video demonstrations to provide an overview of clinical movement disorders.

Non-CME Accredited Educational Activities

Science of Industry Sessions: These interactive sessions will provide attendees with a non-CME educational opportunity to learn about novel therapeutic agents under development by industry. Sessions may incorporate basic scientists or clinicians working in industry, and topics may address the biological rationale or development process for specific therapeutics in development within the field of Movement Disorders.

Sponsored Symposia

Sponsored Symposia: These company-based informational sessions provide attendees with non-CME educational opportunities to learn the latest in therapeutics.

Video Challenge

Video Challenge: The goal of this session is for attendees to learn from a series of unusual patients and observe how senior experts approach a challenging case. A world-renowned panel of Movement Disorders experts guide attendees through unique Movement Disorder cases as they are presented by representatives from Movement Disorder centers around the world.

VIRTUAL CONGRESS FACULTY ROLES

Chair: Facilitates the learnings of the session; ensures that learning objectives are met during the presentation(s), and engages the learners as needed.

CSPC Liaison: Develops the session from the onset; provides guidance to ensure that the learning objectives are met; interacts with Speakers/Presenters to ensure presentations are well integrated and overlap is minimized.

Speaker/Presenter: Creates and delivers the presentation materials, and participates in the dialogue of the session.

2020 VIRTUAL CONGRESS THEME

At each annual International Congress, the Congress Scientific Program Committee selects a theme that is highlighted throughout the meeting. This year’s theme is The Combined Multidisciplinary Approach to Movement Disorders. International experts will serve as faculty, and the meeting participants can elect to attend any or all of these sessions.

Themed sessions
FRIDAY, SEPTEMBER 11, 2020

Welcome Ceremony

15:00 - 16:00 GMT
All participants are encouraged to attend the Virtual Congress Welcome Ceremony.

SATURDAY, SEPTEMBER 12, 2020

MDS-AOS Regional Assembly

6:00 - 6:30 GMT
All participants from Asia and Oceania are encouraged to attend.

101: Therapeutic Plenary Session

Updates on Medical Management Strategies for Parkinson’s Disease: Motor Aspects
12:00 - 14:00 GMT

Chairs: Matthew B. Stern, USA
Pille Taba, Estonia
Early Pharmacologic Management
Oscar Gershanik, Argentina
Rehabilitation Strategies
Alice Nieuwboer, Belgium
Medical Management Strategies for Advancing Disease Patients
Regina Katzenschlager, Austria

CSPC Liaison: Shen Yang Lim, Malaysia

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Discuss current management of early-stage Parkinson’s disease
2. Review the role of rehabilitation, including physical, occupational and speech therapies, and exercise in Parkinson’s disease
3. Describe current medical management strategies for advancing Parkinson’s disease (motor complications and other late-stage features)

MDS Business Meeting

14:00 - 14:30 GMT
All participants are encouraged to attend.

102: Therapeutic Plenary Session

Parkinson’s Disease: Non-Motor Aspects
14:30 – 16:30 GMT

Chairs: Angelo Antonini, Italy
Daniel Weintraub, USA
Neuropsychiatric Features
Anette Schrag, United Kingdom
Dysautonomia
Horacio Kaufmann, USA
Sleep and Fatigue
Ron Postuma, Canada

CSPC Liaison: Jennifer Goldman, USA

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Describe the neuropsychiatric aspects of Parkinson’s disease and their management
2. Discuss the recognition and management of dysautonomia in Parkinson’s disease
3. Summarize the symptoms and management of sleep and fatigue in Parkinson’s disease

103: Therapeutic Plenary Session

Therapeutic Approaches to Chorea, Dystonia, and Myoclonus
18:00 – 20:00 GMT

Chairs: Francisco Cardoso, Brazil
Eduardo Tolosa, Spain
Chorea
Ruth Walker, USA
Dystonia
Rachel Saunders-Pullman, USA
Myoclonus
Yoshikazu Ugawa, Japan

CSPC Liaison: Francisco Cardoso, Brazil

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. List the therapeutic options to manage patients with different types of chorea
2. Discuss the therapeutic management of dystonia
3. Summarize the therapeutic options for myoclonus
SATURDAY, SEPTEMBER 12, 2020

104: Therapeutic Plenary Session

Neurosurgical Management of Movement Disorders
20:30 – 22:30 GMT

Chairs: Günther Deuschl, Germany
Andrea Kühn, Germany

Technical Advances for DBS Treatment
Jens Volkmann, Germany

Long-term Effects of DBS on Motor and Non-motor Symptoms in Parkinson’s Disease
Patricia Limousin, United Kingdom

Alternative Strategies: Focused Ultrasound and Other Lesioning Techniques in Movement Disorders
José Obeso, Spain

CSPC Liaison: Andrea Kühn, Germany

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Discuss and apply new DBS techniques such as segmented leads for current steering, imaging guided programming, VTA models
2. Discuss indications of DBS and explain motor and non-motor benefits and risks
3. Discuss the pros and cons of different surgical approaches in movement disorders

SUNDAY, SEPTEMBER 13, 2020

101: Therapeutic Plenary Session (Encore Presentation)

Updates on Medical Management Strategies for Parkinson’s Disease: Motor Aspects
2:00 – 4:00 GMT

Chairs: Roongroj Bhidayasiri, Thailand
Shengdi Chen, Peoples Republic of China
Oscar Gershanik, Argentina
Alice Nieuwboer, Belgium
Regina Katzenschlager, Austria

Medical Management Strategies for Advancing Disease Patients
Regina Katzenschlager, Austria

CSPC Liaison: Shen Yang Lim, Malaysia

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Discuss current management of early-stage Parkinson’s disease
2. Review the role of rehabilitation, including physical, occupational and speech therapies, and exercise in Parkinson’s disease
3. Describe current medical management strategies for advancing Parkinson’s disease (motor complications and other late-stage features)

102: Therapeutic Plenary Session (Encore Presentation)

Parkinson’s Disease: Non-Motor Aspects
4:30 – 6:30 GMT

Chairs: Huifang Shang, Peoples Republic of China
Louis Tan, Singapore
Annette Schrag, United Kingdom
Horacio Kaufmann, USA
Ron Postuma, Canada

Neuropsychiatric Features
Dysautonomia
Sleep and Fatigue

CSPC Liaison: Jennifer Goldman, USA

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Describe the neuropsychiatric aspects of Parkinson’s disease and their management
2. Discuss the recognition and management of dysautonomia in Parkinson’s disease
3. Summarize the symptoms and management of sleep and fatigue in Parkinson’s disease
103: Therapeutic Plenary Session (Encore Presentation)

**Therapeutic Approaches to Chorea, Dystonia, and Myoclonus**
7:00 – 9:00 GMT

**Chairs:**
- Victor Fung, Australia
- Ruey-Meei Wu, Taiwan
- Chorea
- Ruth Walker, USA
- Dystonia
- Rachel Saunders-Pullman, USA
- Myoclonus
- Yoshikazu Ugawa, Japan

**CSPC Liaison:** Francisco Cardoso, Brazil

**Recommended Audience:** Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. List the therapeutic options to manage patients with different types of chorea
2. Discuss the therapeutics management of dystonia
3. Summarize the therapeutic options for myoclonus

104: Therapeutic Plenary Session (Encore Presentation)

**Neurosurgical Management of Movement Disorders**
9:30 - 11:30 GMT

**Chairs:**
- Ritsuko Hanajima, Japan
- Beomseok Jeon, South Korea
- Technical Advances for DBS Treatment
- Jens Volkmann, Germany
- Long-term Effects of DBS on Motor and Non-motor Symptoms in Parkinson's Disease
- Patricia Limousin, United Kingdom
- Alternative Strategies: Focused Ultrasound and Other Lesioning Techniques in Movement Disorders
- José Obeso, Spain

**CSPC Liaison:** Andrea Kühn, Germany

**Recommended Audience:** Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Discuss and apply new DBS techniques such as segmented leads for current steering, imaging guided programming, VTA models
2. Discuss indications of DBS and explain motor and non-motor benefits and risks
3. Discuss the pros and cons of different surgical approaches in movement disorders

201: Plenary Session

**Presidential Lectures**
12:00 – 14:00 GMT

**Chairs:**
- Francisco Cardoso, Brazil
- Claudia Trenkwalder, Germany
- Stanley Fahn Lecture
- Werner Poewe, Austria
- C. David Marsden Lecture
- Hiroshi Shibasaki, Japan
- Junior Award Lectures
- To Be Announced

**CSPC Liaison:** Vincenzo Bonifati, Netherlands
- Claudia Trenkwalder, Germany

**Recommended Audience:** Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

14:00 - 14:30 GMT
All participants from Europe are encouraged to attend.

301: Parallel Session

**COVID -19 and Movement Disorders**
14:30 – 16:30 GMT

**Chairs:**
- Huifang Shang, Peoples Republic of China
- Indu Subramanian, USA
- Elena M. Moro, France
- COVID-19 in Patients with Parkinson's Disease or Movement Disorders
- Alfonso Fasano, Canada
- Caring of Patients with Movement Disorders in the COVID-19 Era
- Esther Cubo, Spain

**CSPC Liaison:** Buz Jinnah, USA

**Recommended Audience:** Clinical Academicians, Practitioners Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Summarize the current knowledge about the neurological manifestations and neuropathology in subjects affected by the COVID-19
2. Summarize the clinical phenomenology and outcomes of the COVID-19 disease in patients with Parkinson’s disease and other movement disorders
3. Discuss the impact of the COVID-19 pandemic on the clinical care of patients with movement disorders, and the available strategies to ensure continuity of care and best outcomes
SUNDAY, SEPTEMBER 13, 2020

**302: Parallel Session**

**MSA and Pure Autonomic Failure**

14:30 – 16:30 GMT

**Chairs:**
- Howard Hurtig, USA
- Ryosuke Takahashi, Japan

- Molecular Mechanisms
- Virginia Lee, USA
- The Challenge of Early Diagnosis
- Wassilios Meissner, France
- Pure / Isolated Autonomic Failure
- Lucy Kaufmann, USA

**CSPC Liaisons:**

- Pietro Cortelli, Italy
- Ryosuke Takahashi, Japan

**Recommended Audience:** Basic Scientists, Clinical Academicians, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Discuss the role of alpha-synuclein in the initiation and progression of neurodegeneration across Parkinson's disease and atypical parkinsonism
2. Recognize Multiple System Atrophy at an early stage
3. Recognize Pure/Isolated Autonomic failure and discuss its role in predicting the onset of other synucleinopathies (MSA, DLB, PD)

**303: Parallel Session**

**Update on Functional Movement Disorders**

14:30 – 16:30 GMT

**Chairs:**
- Mark Edwards, United Kingdom
- Mark Hallett, USA

- Phenomenology
- Francesca Morgante, United Kingdom
- Electrophysiology and Imaging
- Tereza Serranova, Czech Republic
- Psychological Aspects to Aetiology and Management
- Timothy Nicholson, United Kingdom

**CSPC Liaison:**

- Beomseok Jeon, South Korea

**Recommended Audience:** Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Recognize the phenomenology of functional movement disorders
2. Summarize the electrophysiological and imaging features of functional movement disorders
3. Discuss the psychopathology and management of functional movement disorders

**304: Parallel Session**

**Update on Genetics of Movement Disorders**

14:30 – 16:30 GMT

**Chairs:**
- Christine Klein, Germany
- Carolyn Sue, Australia

- Parkinsonism
- Chin-Hsien Lin, Taiwan
- Dystonia
- Patricia Maria Carvalho Aguiar, Brazil
- Ataxia
- Martin Paucar Arce, Sweden

**CSPC Liaison:**

- Carolyn Sue, Australia

**Recommended Audience:** Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Summarize recently identified genes related to Parkinson's disease and parkinsonism
2. Summarize recently identified genes related to dystonia
3. Summarize recently identified genes related to ataxia

**305: Parallel Session**

**Heterogeneity of Parkinson's Disease: Clinical Phenotypes and Progression**

14:30 – 16:30 GMT

**Chairs:**
- Nabila Dahodwala, USA
- Connie Marras, Canada

- Influence of the Genetic Determinants
- Clemens Scherzer, USA
- Role of Environment, Lifestyle and Comorbidities
- Connie Marras, Canada
- Lessons from Large Cohort Studies
- Rodolfo Savica, USA

**CSPC Liaison:**

- Claudia Trenkwalder, Germany

**Recommended Audience:** Basic Scientists, Clinical Academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Discuss the influence of different genetic variants (rare/Mendelian, intermediate-effects variants such as GBA and LRRK2-G2019S, and common GWAS variants) on phenotypes and progressions of Parkinson's disease
2. Discuss the influence of environment, diet, exercise, comorbidities and inflammation on the heterogeneity of Parkinson's disease
3. Discuss the potential of ongoing large longitudinal cohorts-studies to understand Parkinson's disease heterogeneity
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Date and Time</th>
<th>Chairs</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>306: Parallel Session</strong></td>
<td>Huntington's Disease Continuum and Non-Huntington's Choreas</td>
<td>14:30 – 16:30 GMT</td>
<td>Joaquim Ferreira, Portugal; Amanda Krause, South Africa</td>
<td>The Natural History of Huntington's Disease&lt;br&gt;G. Bernhard Landwehrmeyer, Germany&lt;br&gt;When Genetic Testing is Negative: Huntington's Phenocopies&lt;br&gt;Amanda Krause, South Africa&lt;br&gt;A Critical Appraisal of Clinical Trials in Huntington's Disease&lt;br&gt;Joaquim Ferreira, Portugal&lt;br&gt;&lt;br&gt;CSPC Liaison: Francisco Cardoso, Brazil&lt;br&gt;Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees&lt;br&gt;At the conclusion of this session, participants should be better able to:&lt;br&gt;1. Discuss the natural history of Huntington’s Disease&lt;br&gt;2. List the differential diagnosis of Huntington’s Disease phenocopies&lt;br&gt;3. Appraise recent clinical trials in Huntington’s Disease</td>
</tr>
<tr>
<td><strong>401: Teaching Course</strong></td>
<td>Cognitive and Psychiatric Issues in the Parkinsonian Spectrum</td>
<td>14:30 – 16:30 GMT</td>
<td>Cristian Falup-Pecurariu, Romania; James Morley, USA</td>
<td>Apathy: Why, Who, and What to Do About It&lt;br&gt;Marcelo Merello, Argentina&lt;br&gt;It’s Not Just MCI / Dementia: The Many Cognitive Changes in Parkinsonism&lt;br&gt;Madeleine Sharp, Canada&lt;br&gt;Parkinson’s Disease Treatments: How do They Change Neuropsychiatric Symptoms?&lt;br&gt;Daniel Weintraub, USA&lt;br&gt;&lt;br&gt;CSPC Liaison: Ron Postuma, Canada&lt;br&gt;Recommended Audience: Clinical Academicians, Practitioners, Students/Residents/Trainees&lt;br&gt;At the conclusion of this session, participants should be better able to:&lt;br&gt;1. Discuss the pathophysiology, disease spectrum and management of apathy in parkinsonian conditions&lt;br&gt;2. Evaluate the broad spectrum of non-dementia cognitive changes in parkinsonian conditions&lt;br&gt;3. Differentiate treatment vs. disease-related effects on neuropsychiatric symptoms in Parkinson’s disease</td>
</tr>
<tr>
<td><strong>402: Teaching Course</strong></td>
<td>Dystonia, Ataxia, and Tics</td>
<td>14:30 – 16:30 GMT</td>
<td>Cynthia Comella, USA; Susanne Schneider, Germany</td>
<td>My Approach to Dystonia&lt;br&gt;Susanne Schneider, Germany&lt;br&gt;My Approach to Ataxia&lt;br&gt;Jose Luiz Pedroso, Brazil&lt;br&gt;My Approach to Tic Disorders&lt;br&gt;Tamara Pringsheim, Canada&lt;br&gt;&lt;br&gt;CSPC Liaison: Ron Postuma, Canada&lt;br&gt;Recommended Audience: Clinical Academicians, Practitioners, Students/Residents/Trainees&lt;br&gt;At the conclusion of this session, participants should be better able to:&lt;br&gt;1. Describe the phenomenology and diagnostic approach to dystonia&lt;br&gt;2. Describe the phenomenology and diagnostic approach to ataxia&lt;br&gt;3. Summarize the phenomenology and diagnostic approach to tic disorders</td>
</tr>
<tr>
<td><strong>MDS-Africa Regional Assembly</strong></td>
<td></td>
<td>17:30 - 18:00 GMT</td>
<td></td>
<td>All participants from the African continent are encouraged to attend.</td>
</tr>
<tr>
<td><strong>501: Skills Workshop</strong></td>
<td>A Multidisciplinary Approach for Palliative Care</td>
<td>18:00 – 19:30 GMT</td>
<td>Stefan Lorenzl, Germany; Janis Miyasaki, Canada</td>
<td>This session aims to help providers identify and manage palliative care needs, collaborate with other allied healthcare team members, and develop advance care planning with patients, families and their caregivers.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CSPC Liaison: Claudia Trenkwalder, Germany&lt;br&gt;Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees&lt;br&gt;At the conclusion of this session, participants should be better able to:&lt;br&gt;1. Recognize the relevance of palliative care in movement disorders&lt;br&gt;2. Develop a multidisciplinary approach to the management of patients in advanced care</td>
</tr>
</tbody>
</table>
SUNDAY, SEPTEMBER 13, 2020

502: Skills Workshop

DBS and Functional Communication in Parkinson’s Disease: Insights and Intervention
18:00 – 19:30 GMT
In this interactive session, the faculty will examine the impact of deep brain stimulation on speech intelligibility in Parkinson’s disease. Evidence-based interventions will be compared to optimize functional communication.
Elina Tripoliti, United Kingdom
Michelle Troche, USA
CSPC Liaison: Terry Ellis, USA
Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Examine the impact of deep brain stimulation on speech intelligibility in Parkinson’s disease
2. Compare treatment strategies to optimize functional communication in Parkinson’s disease

601: Special Topics in Movement Disorders

Big Data Analytics in Clinical Research for Movement Disorders
18:00 – 19:30 GMT
In this session the Faculty will discuss the impact of big data analytics in the current clinical research on Parkinson’s disease and other movement disorders, as well as the potential implications of the research findings in the clinical management.
Ivo Dinov, USA
Allison Willis, USA
CSPC Liaison: Roongroj Bhidayasiri, Thailand
Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Describe the concept of big data analytics and the impact in clinical research in the field of movement disorders
2. Discuss findings from studies based on big data analytics, and their potential implications in the clinical management

503: Skills Workshop

Imaging in Parkinson’s Disease
18:00 – 19:30 GMT
In this interactive session, the faculty will review the nuts and bolts of how radioisotope imaging, MRI, and ultrasonography are used for diagnosis and prognostication in Parkinson’s disease.
Marios Politis, United Kingdom
Klaus Seppi, Austria
CSPC Liaison: Per Borghammer, Denmark
Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Describe how PET and SPECT are used for the diagnosis, prognostication, and as progression markers of Parkinson’s disease
2. Describe the application of anatomical and functional MRI, and ultrasonography in the diagnosis, prognostication, and as progression markers of Parkinson’s disease

602: Special Topics in Movement Disorders

Revisiting the Role of Non-Neuronal Cells in Parkinson’s Disease
18:00 – 19:30 GMT
In this interactive session, the faculty will discuss recent data suggesting that brain non-neuronal cells, including glial and inflammatory cells, are involved in the pathogenesis and pathophysiology of Parkinson’s disease.
Antonella Consiglio, Spain
David Sulzer, USA
CSPC Liaison: Etienne Hirsch, France
Recommended Audience: Basic Scientists, Clinical Academicians, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Discuss the roles for non-neuronal cells in the pathophysiology of Parkinson’s disease
2. Describe the putative roles for non-neuronal cells in the pathogenesis

504: Skills Workshop

Phenomenology of Movement Disorders for Young Neurologists: Semiological Tricks and Pitfalls
18:00 – 19:30 GMT
In this interactive session, the faculty will discuss tricks and maneuvers they employ in clinical practice for the detection and examination of Movement Disorders.
Mayela Rodriguez Violante, Argentina
Oscar Gershank, Mexico
CSPC Liaison: Andrea Kühn, Germany
Recommended Audience: Practitioners, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Explore the phenomenology of Movement Disorders
2. Apply semiological tricks to better detect and examine Movement Disorders

701: Video Session

Gait Disorders
18:00 – 19:30 GMT
In this interactive session, participants will gain knowledge on different gait disorders through illustrative videos. Key features of gait disorders and different treatment strategies will be discussed, including surgical interventions.
Nir Giladi, Israel
Evzen Ruzicka, Czech Republic
CSPC Liaison: Andrea Kühn, Germany
Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Review the clinical features of normal gait and recognize key abnormalities of gait disorders
2. Recognize specific dysfunction in gait disorders, discuss differential diagnosis and the respective therapeutic management
SUNDAY, SEPTEMBER 13, 2020

702: Video Session

Tardive Syndromes and Other Drug Induced Movement Disorders
18:00 – 19:30 GMT

In this interactive session, the faculty will demonstrate iatrogenic movement disorders in a case-based format, highlighting acute, chronic, and tardive syndromes, emphasizing phenotypic features that can be overlooked or misattributed to other disorders. Pearls and pitfalls of drug-related complications will be discussed.

Hubert Fernandez, USA
Deborah Hall, US

CSPC Liaison: Alberto Espay, USA

Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Recognize typical and atypical forms of tardive syndromes and distinguish from mimics
2. Identify clinical clues associated with drug-induced movement disorders

MDSTM Video Challenge (non CME)

19:30 – 22:30 GMT

Please join Masters of Ceremony Anthony Lang and Kapil Sethi as they host world-renowned Movement Disorders experts in guiding participants through unique Movement Disorder cases.

The cases will be presented by representatives from Movement Disorder Centers around the world and discussed by Movement Disorder Experts. Awards will be given for the most interesting and challenging cases. Country pride will add an enjoyable spirit of competition to this event. The goal of this session is for participants to learn from a series of unusual, very interesting patients and see how senior experts approach these types of challenging cases.

Featured Experts:
Bettina Balint, United Kingdom
Orlando Barsottini, Brazil
Kailash Bhatia, United Kingdom
Francisco Cardoso, Brazil
Roberto Erro, Italy
Alberto Espay, USA
Alfonso Fasano, Canada
Jennifer Friedman, USA
Victor Fung, Australia
Christos Ganos, Germany
Dan Healy, Ireland
Marina Koning-Tijssen, Netherlands
Manju Kurian, United Kingdom
Tim Lynch, Ireland
Werner Poewe, Austria
Stephen Reich, USA
Maria Stamelou, Greece
MONDAY, SEPTEMBER 14, 2020

**MDS Video Challenge (Encore Presentation)**

2:00 – 5:00 GMT

Please see page page 15 for complete description.

**202: Plenary Session**

**Treatable, Rare Movement Disorders Not to Miss**

12:00 – 14:00 GMT

*Chairs:*
- Victor Fung, Australia
- Mayela Rodriguez-Violante, Mexico

- **Clinical Approach**
  - Jennifer Friedman, USA
- **Diagnostic Workup**
  - Manju Kurian, United Kingdom
- **Current and Future Treatments**
  - Buz Jinnah, USA

*CSPC Liaison: Maria Stamelou, Greece*

*Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees*

At the conclusion of this session, participants should be better able to:

1. Appraise clinically a patient with a suspected treatable, rare movement disorder and recognize clinical clues not to be missed
2. Decide, determine and interpret the necessary investigations for a patient with a suspected treatable, rare movement disorder
3. Apply current therapies and identify upcoming new therapy options for rare movement disorders

**203: Plenary Session**

**Parkinson’s Disease Biomarkers: A Multidisciplinary Approach**

12:00 – 14:00 GMT

*Chairs:*
- Per Borghammer, Denmark
- Andrew Siderowf, USA

- **Update on Imaging Biomarkers for Parkinson’s Disease**
  - A. Jon Stoessl, Canada
- **Clinical Utility of Fluid Biomarkers for Parkinson’s Disease**
  - Brit Mollenhauer, Germany
- **Peripheral Pathology as a Parkinson’s Disease Biomarker**
  - Charles Adler, USA

*CSPC Liaison: Andrew Siderowf, USA*

*Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees*

At the conclusion of this session, participants should be better able to:

1. Evaluate the clinical value of imaging biomarkers, including emerging PET and SPECT ligands and MRI
2. Describe current status of biochemical biomarkers for Parkinson’s disease
3. Summarize recent developments in peripheral tissue assays for alpha-synuclein pathology in Parkinson’s disease

**307: Parallel Session**

**Innovative Models in the Integrated Management of Parkinson’s Disease**

14:30 – 16:30 GMT

*Chairs:*
- Bastiaan Bloem, Netherlands
- Terry Ellis, USA

- **Interdisciplinary Team Models of Care in Parkinson’s Disease**
  - Jennifer Goldman, USA
- **An Integrated Telemedicine Approach in Parkinson’s Disease**
  - Mark Guttman, Canada
- **Integrated Palliative Care in Parkinson’s Disease: Timing Matters**
  - Maya Katz, USA

*CSPC Liaison: Terry Ellis, USA*

*Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees*

At the conclusion of this session, participants should be better able to:

1. Describe interdisciplinary team models of care to optimize the management of Parkinson’s disease
2. Discuss innovative models on integrated care using telehealth in Parkinson’s disease
3. Describe a palliative care model integrated over the disease continuum in Parkinson’s disease

**308: Parallel Session**

**Sleep Disorders in Parkinsonism: Science and Clinical Aspects**

14:30 – 16:30 GMT

*Chairs:*
- Roongroj Bhidayasiri, Thailand
- Ron Postuma, Canada

- **Basic Science Aspects of RBD**
  - Pierre Luppi, France
- **Clinical Aspects of RBD**
  - Ambra Stefani, Austria
- **Sleep Disorders in Atypical Parkinsonism**
  - Federica Provini, Italy

*CSPC Liaison: Per Borghammer, Denmark*

*Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees*

At the conclusion of this session, participants should be better able to:

1. Describe the pathophysiology and neuropathology underlying RBD
2. Describe clinical manifestations of RBD, their relationship with other clinical features, and management
3. Describe prominent sleep disorders in atypical Parkinsonisms, their relation with other clinical features, and management
MONDAY, SEPTEMBER 14, 2020

### 309: Parallel Session

**Update on Recent Clinical Trials**
14:30 – 16:30 GMT

Chairs: Hubert Fernandez, USA
Oscar Gershanik, Argentina
Tatjana Simuni, USA

Atypical Parkinsonian Disorders
Günter Höglinger, Germany

Huntington’s Disease
Blair Leavitt, Canada

At the conclusion of this session, participants should be better able to:
1. Discuss recent clinical trials in Parkinson’s disease
2. Review recent clinical trials for atypical parkinsonian disorders
3. Discuss recent clinical trials for hyperkinetic movement disorders

### 310: Parallel Session

**The Crossroads of Spasticity and Ataxia**
14:30 – 16:30 GMT

Chairs: Orlando Barsottini, Brazil
Brent Fogel, USA

Clinical Syndromes and Diagnostic Evaluation
To Be Announced

Biological Basis
Brent Fogel, USA

Management
Carlos Henrique Camargo, Brazil

At the conclusion of this session, participants should be better able to:
1. Describe the clinical features and diagnostic workup of syndromes that feature spasticity and ataxia
2. Summarize the pathogenesis of spasticity and ataxia
3. Describe management strategies for clinical syndromes that combine spasticity and ataxia

### 311: Parallel Session

**Advanced Multi-Modal Imaging and Big Imaging Data in Parkinson’s Disease**
14:30 – 16:30 GMT

Chairs: A. Jon Stoessl, Canada
Antonio Strafella, Canada

Multi-Modal Imaging of the Braak Stages and Parkinson’s Disease Subtypes
Per Borghammer, Denmark

Multi-Modal Imaging for Diagnosis, Prognosis and Progression
Jee-Young Lee, South Korea

Simulating Parkinson’s Disease in Computer Models and Using A.I. for Big Imaging Data
Alain Dagher, Canada

At the conclusion of this session, participants should be better able to:
1. Describe how multi-modal imaging enables visualization of damage to distinct neurotransmitter systems in Parkinson’s disease
2. Describe how multi-modal MRI and other imaging techniques are used for diagnosis, prognostication, and as progression markers
3. Describe computer simulations of Parkinson’s disease and how artificial intelligence algorithms allow in-depth analysis of very large imaging datasets

### 403: Teaching Course

**Atypical Parkinsonisms: Clinical Overview**
14:30 – 16:30 GMT

Chairs: Carlo Colosimo, Italy
John Duda, USA

PSP/CBD
Marina Picillo, Italy

MSA
Han-Joon Kim, South Korea

Clinical Look-Alikes
Kailash Bhatia, United Kingdom

At the conclusion of this session, participants should be better able to:
1. Evaluate the clinical spectrum and imaging features of PSP/CBD
2. Evaluate the clinical spectrum and imaging features of MSA
3. Discuss the disorders which can clinically mimic PSP, CBD, and MSA
MONDAY, SEPTEMBER 14, 2020

404: Teaching Course
Update on Neurosurgery for Movement Disorders
14:30 – 16:30 GMT
Chairs: Elena Moro, France
Michael Okun, USA
DBS for Parkinson’s Disease: Who, Where, and How?
Michael Okun, USA
DBS for Dystonia: Who, Where, and How?
Andrea Kühn, Germany
DBS and Lesioning in Tremor
Günther Deuschl, Germany
CSPC Liaison: Ron Postuma, Canada
Recommended Audience: Basic Scientists, Clinical Academicians, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Identify good candidates for DBS surgery in PD, the best surgical target, and novel types of segmented lead technology
2. Identify good candidates for DBS in dystonia, the outcome over the long term, and novel types of adaptive stimulation
3. Identify how to select candidates for surgery in tremor, how to use DBS, and when surgical vs. ultrasound lesioning should be used

901: Science of Industry (non-CME)
Antisense Oligonucleotides for Treating Movement Disorders
14:30 – 16:30 GMT
See page page 26 for complete session information.

506: Skills Workshop
Botulinum Toxins: A Case-Based Approach
18:00 – 19:30 GMT
In this interactive session, the faculty will use a case-based approach to describe the use of botulinum toxins for the most common forms of dystonia and spasticity.
Carlo Colosimo, Italy
Andres Deik, USA
CSPC Liaison: Buz Jinnah, USA
Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Describe optimal strategies for the application of botulinum toxins for the more common forms of dystonia such as cervical dystonia, blepharospasm, and limb dystonia
2. Describe the optimal strategies for the application of botulinum toxins for the treatment of the more common forms of spasticity affecting the upper and lower limb

507: Skills Workshop
New Perspectives on Phenotype-Genotype Relationships
18:00 – 19:30 GMT
In this interactive session, faculty will describe various types of genotype-phenotype relationships, how to apply genetic testing for diagnosis in different movement disorders, and several online tools available for understanding the outcomes of genetic testing.
Pedro Gonzalez-Alegre, USA
Joanne Trinh, Germany
CSPC Liaison: Buz Jinnah, USA
Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Describe the sometimes complex relationships between various genotypes and their associated phenotypes
2. Describe some of the tools available to help the clinician make better use of the results of genetic testing for diagnosis

505: Skills Workshop
Managing Comorbidities and Polypharmacy Issues in Parkinson’s Disease
18:00 – 19:30 GMT
In this interactive session, the faculty will discuss common comorbidities and the polypharmacy these lead to in the management of Parkinson’s disease.
David Burn, United Kingdom
Tove Henriksen, Denmark
CSPC Liaison: Tove Henriksen, Denmark
Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Recognize the most common comorbidities in Parkinson’s disease
2. Manage the comorbidities and the related polypharmacy in Parkinson’s disease
MONDAY, SEPTEMBER 14, 2020

603: Special Topics in Movement Disorders

Physical Exercise and Parkinson's Disease
18:00 – 19:30 GMT

In this interactive session, the faculty will discuss the role of physical exercise in modifying the risk of developing Parkinson’s disease and the disease progression.

Terry Ellis, USA
Priya Jagota, Thailand

CSPC Liaison: Beomseok Jeon, South Korea

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Discuss the role of physical exercise in modifying the risk for developing Parkinson’s disease
2. Discuss the role of exercise in modifying Parkinson’s disease progression

604: Special Topics in Movement Disorders

Setting Up Your Telemedicine Clinic
18:00 – 19:30 GMT

In this interactive session, participants will gain practical knowledge on the resources needed to set up a telemedicine clinic. Faculty will also discuss both the advantages and disadvantages of this interface for delivery of care and highlight obstacles, potential pitfalls, and opportunities for future enhancements.

Piu Chan, People’s Republic of China
Nijdeka Okubadejo, Nigeria
Meredith Spindler, USA

CSPC Liaison: Alberto Espay, USA

Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Apply readily available technology resources into an interface for telemedicine
2. Recognize the challenges and opportunities of a telemedicine clinic

605: Special Topics in Movement Disorders

How to Become a Successful Movement Disorders Specialist
18:00 – 19:30 GMT

In this interactive session, participants will gain insight on the best approaches to pursue a career in Movement Disorders.

Beomseok Jeon, South Korea
Pille Taba, Estonia

CSPC Liaison: Oscar Gershanik, Argentina

Recommended Audience: Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Choose the right career path, and acquire the necessary skills to become a successful Movement Disorders Specialist
2. Recognize the importance of searching for good mentors when pursuing specialization

703: Video Session

Eye Movement Disorders
18:00 – 19:30 GMT

In this interactive session, attendees will learn bedside examination techniques, recognize categories of abnormal eye movements, and become familiar with ocular and oculomotor abnormalities in many movement disorders.

Tim Anderson, New Zealand
Joyce Liao, USA

CSPC Liaison: Shen Yang Lim, Malaysia

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Undertake a bedside neuro-opthalmological examination relevant to movement disorders
2. Describe characteristic clinical ocular and eye movement abnormalities that aid diagnosis in common and uncommon movement disorders

704: Video Session

Movement Disorder Emergencies
18:00 – 19:30 GMT

In this interactive session, the faculty will show videos of hypokinetic and hyperkinetic movement disorder emergencies, and discuss the practical management of these conditions.

Steven Frucht, USA
Asha Kishore, India

CSPC Liaison: Roongroj Bhidayasiri, Thailand

Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Recognize clinical settings and signs of hypokinetic and hyperkinetic movement disorder emergencies, including those related to device-aided therapies
2. Outline management strategies of various movement disorder emergencies
TUESDAY, SEPTEMBER 15, 2020

**204: Plenary Session**

**Neuroscience Bridges**  
12:00 – 14:00 GMT  

Chairs:  
Vincenzo Bonifati, Netherlands  
Etienne Hirsch, France  

Speakers:  
Karl Deisseroth, USA  
Beth Stevens, USA  

CSPC Liaison:  
Vincenzo Bonifati, Netherlands  
Etienne Hirsch, France  

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

**312: Parallel Session**

The Evolving Spectrum of Movement Disorder Tauopathies  
14:30 – 16:30 GMT  

Chairs:  
Adam Boxer, USA  
Maria Stamelou, Greece  
Clinical Spectrum  
Maria Stamelou, Greece  
Biomarkers  
James Rowe, United Kingdom  
Therapeutic Pipeline  
Adam Boxer, USA  

CSPC Liaison:  
Wassilios Meissner, France  

Recommended Audience: Clinical Academicians, Practitioners, Students/Residents/Trainees  

At the conclusion of this session, participants should be better able to:  
1. Recognize the spectrum of movement disorder tauopathies  
2. Discuss biomarkers for movement disorder tauopathies  
3. Describe the therapeutics pipeline for movement disorder tauopathies

**313: Parallel Session**

Essential Tremor, Dystonia and Their Relationships  
14:30 – 16:30 GMT  

Chairs:  
Kailash Bhatia, United Kingdom  
Louis Tan, Singapore  

Clinical Spectrum  
Maria Stamelou, Greece  
Biomarkers  
James Rowe, United Kingdom  
Therapeutic Pipeline  
Adam Boxer, USA  

CSPC Liaison:  
Maria Stamelou, Greece  

Recommended Audience: Clinical Academicians, Practitioners, Students/Residents/Trainees  

At the conclusion of this session, participants should be better able to:  
1. Describe and recognize the phenotypic spectrum of essential tremor-plus syndromes  
2. Examine and identify the characteristics of tremor in a patient with dystonia  
3. Evaluate neurophysiological tools for the differential diagnosis of essential tremor and dystonia syndromes

**314: Parallel Session**

Microbiome and the Gut-Brain Axis  
14:30 – 16:30 GMT  

Chairs:  
Carolyn Sue, Australia  
Ruey-Mei Wu, Taiwan  

The Gut Microbiome in Health and Disease  
Filip Scheperjans, Finland  
The Gut Microbiome in the Pathogenesis of Parkinson’s Disease  
Heinz Reichmann, Germany  
Perspectives for Clinical Management  
Ai Huey Tan, Malaysia  

CSPC Liaison:  
Carolyn Sue, Australia  

Recommended Audience: Basic Scientists, Clinical Academicians, Students/Residents/Trainees  

At the conclusion of this session, participants should be better able to:  
1. Summarize the scientific evidence for the role of the gut microbiome in health and disease  
2. Appraise animal studies investigating the role of the gut microbiome in the pathogenesis of Parkinson’s disease  
3. Appraise clinical studies investigating the role of the gut microbiome in the pathogenesis of Parkinson’s disease
TUESDAY, SEPTEMBER 15, 2020

315: Parallel Session
DNA Repeat Expansions: Old and New Forms
14:30 – 16:30 GMT
Chairs: Thomas Klockgether, Germany
Henry Paulson, USA
Genotypes and Phenotypes
Thomas Klockgether, Germany
Molecular Mechanisms
Henry Paulson, USA
Emerging Therapeutics Avenues
Edward Wild, United Kingdom
CSPC Liaison: Jennifer Friedman, USA
Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Recognize the genetic and clinical spectrum of repeat expansions in movement disorders
2. Describe the molecular mechanisms of repeat expansion disorders
3. Describe the emerging therapeutic avenues for repeat expansion disorders

316: Parallel Session
Dementia with Lewy Bodies (DLB)
14:30 – 16:30 GMT
Chairs: Melissa Armstrong, USA
Karen Marder, USA
Genetics Insights to the Pathogenesis
Rita Guerreiro, United Kingdom
Imaging
Kejal Kantarci, USA
Diagnosis and Management
Melissa Armstrong, USA
CSPC Liaison: Karen Marder, USA
Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Recognize the role of genetic variants in the pathogenesis of Lewy Body disorders
2. Discuss the role of imaging in differential diagnosis of Lewy Body disorders
3. Identify multidisciplinary approaches to Lewy Body disorders

317: Parallel Session
Gene-driven Therapies Under Development for Parkinson’s Disease
14:30 – 16:30 GMT
Chairs: Etienne Hirsch, France
Dan Kremens, USA
At the Crossroads Between Gaucher’s and Parkinson’s Disease
Ellen Sidransky, USA
LRRK2 Inhibition as a Target for Intervention in Parkinson’s Disease
Elisa Greggio, USA
Alpha-synuclein Aggregation as a Target for Therapeutic Intervention
Daniel Otzen, Denmark
CSPC Liaison: Tiago Outeiro, Germany
Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Discuss the role of GBA1 as a genetic risk factor and target for intervention in Parkinson’s disease
2. Discuss the current status of LRRK2 inhibition as a therapeutic strategy for Parkinson’s disease
3. Compare different possible therapeutic strategies targeting alpha-synuclein aggregation

405: Teaching Course
Parkinson’s Disease Biomarkers
14:30 – 16:30 GMT
Chairs: Shengdi Chen, People’s Republic of China
Brit Mollenhauer, Germany
What Makes a Good Biomarker?
Michele Hu, United Kingdom
Key Updates in Fluid and Tissue Biomarkers of Parkinson’s Disease
Alice Chen-Plotkin, USA
Key Updates in Imaging Biomarkers
Kathleen Poston, USA
CSPC Liaison: Ron Postuma, Canada
Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Discuss different types and uses of biomarkers in Parkinson’s disease
2. Summarize key updates in the field of Parkinson’s disease fluid and tissue biomarkers
3. Summarize updates in the field of Parkinson’s disease neuroimaging biomarkers
TUESDAY, SEPTEMBER 15, 2020

406: Teaching Course

**Autonomic Disturbances in Movement Disorders**
14:30 – 16:30 GMT

Chairs: Pietro Cortelli, Italy
David Goldstein, USA

Physiology and Pathophysiology
David Goldstein, USA

Clinical Evaluation and Diagnostic Tests
Valeria Iodice, United Kingdom

Management
Pietro Cortelli, Italy

CSPC Liaison: Ron Postuma, Canada

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Recognize the important movement disorders associated with autonomic dysfunction
2. Discuss clinical testing for autonomic dysfunction in movement disorders
3. Evaluate pathophysiology and treatment options for autonomic dysfunction in movement disorders

509: Skills Workshop

**How to Use the MDS-UPDRS**
18:00 – 19:30 GMT

In this interactive session, movement disorders experts will facilitate the understanding of participants on the core elements of the MDS-UPDRS and enable them to become fluent in the grading system. Participants will have an opportunity to practice on test cases and determine how to use this standardized measure to optimize clinical and research evaluations, train others in a standardized assessment of Parkinson’s disease, and increase communication amongst providers.

Emilia Gatto, Argentina
Matej Skorvanek, Slovakia

CSPC Liaison: Veronica Santini, USA

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Evaluate patients and participants in clinical and research settings with the MDS-UPDRS
2. Practice using the MDS-UPDRS through interactive exercises and test cases

508: Skills Workshop

**Genetic Testing, Counseling and Ethical Issues**
18:00 – 19:30 GMT

In this interactive session, the faculty will discuss basic issues regarding genetic testing and counseling for movement disorders, including the rationale, process, challenges and ethical concerns, such as privacy and testing minors, that may arise. Faculty will provide insights regarding ethical aspects of genetics in movement disorders in the next generation sequencing era. Case examples will be used to illustrate the pros and cons of genetic testing, ethical considerations, and challenges faced by clinicians, geneticists, and patients and their families.

Roy Alcalay, USA
Christine Klein, Germany
Avi Orr-Urtreger, Israel

CSPC Liaisons: Jennifer Goldman, USA
Karen Marder, USA

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Discuss genetic testing and counseling for movement disorders, including the “when, what, why, and how”
2. Recognize the ethical issues relevant to genetic testing and the management of patients with movement disorders

509: Skills Workshop

**Lessons From My Patients**
18:00 – 19:30 GMT

Session Description: In this interactive session, experienced clinical specialists will discuss important lessons they have learned from patients, analyzing the important clinical features of the history and examination that aided in the diagnosis, as well as pitfalls of the evaluation process. Faculty will also discuss approaches to management and key features that assist in determining appropriate strategies.

Cynthia Comella, USA
Marie Vidailhet, France

CSPC Liaisons: Tove Henriksen, Denmark
Veronica Santini, USA

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Interpret and critique the pertinent historical and examination elements that may be advantageous when diagnosis and management are elusive
2. Identify common pitfalls in the evaluation of movement disorders
606: Special Topics in Movement Disorders

Autonomic Dysfunction: Pathophysiology and Advanced Testing
18:00 – 19:30 GMT

In this interactive session, the pathophysiology and advanced methods for investigating, diagnosing and imaging cardiovascular, gastrointestinal and urogenital systems in Parkinson’s disease and atypical parkinsonism will be illustrated. Participants will be able to discuss the relevance of advanced diagnostic techniques to define and manage neurogenic orthostatic hypotension, gastrointestinal and urogenital dysfunctions.

Ryuji Sakakibara, Japan
Paola Sandroni, USA

CSPC Liaison: Pietro Cortelli, Italy

Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Assess the pathophysiology of neurogenic orthostatic hypotension, gastrointestinal and urogenital autonomic dysfunctions
2. Interpret the results of advanced investigations for planning appropriate management of these autonomic dysfunctions

607: Special Topics in Movement Disorders

IPCs and Organoids for Parkinson’s Disease
18:00 – 19:30 GMT

In this session, the technology of induced pluripotent stem cells (iPS) and brain organoids as innovative tools for Parkinson’s disease modeling and development of novel therapies will be discussed.

Wado Akamatsu, Japan
Eng-King Tan, Singapore

CSPC Liaison: Ryouzuke Takahashi, Japan

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Illustrate the application of human pluripotent stem cell technology and brain organoids to study the molecular mechanisms of Parkinson’s disease
2. Discuss the potential of human pluripotent stem cell and organoid technologies for the development of novel therapies for Parkinson’s disease

608: Special Topics in Movement Disorders

Metals and Calcium in my Brain
18:00 – 19:30 GMT

In this interactive session the presenters will discuss clinical and imaging aspects of movement disorders related to iron, copper, manganese, and calcium brain accumulation. The audience will learn important tips to clinically distinguish different forms of these disorders and the available treatment options.

Annu Aggarwal, India
Miryam Carecchio, Italy

CSPC Liaison: Orlando Barsottini, Brazil

Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Discuss the phenotypic spectrum of movement disorders associated with brain metal accumulations
2. Recognize different imaging hallmarks of these disorders

609: Special Topics in Movement Disorders

Nutrition and Microbiome in Health and Neurodegenerative Disease
18:00 – 19:30 GMT

In this interactive session, faculty will discuss nutrition and the microbiome in health and disease. They will present research on nutrition and dietary patterns and their effects on maintaining health and the development of disease, cognitive decline, and parkinsonism. Faculty will discuss the microbiome and how it relates to the pathogenesis of Parkinson’s disease, different fecal and blood microbiota in animal and human models, and implications for research and clinical care.

John Duda, USA
Qin Xiao, People’s Republic of China

CSPC Liaison: Jennifer Goldman, USA

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Describe how nutrition and different dietary patterns influence both health and disease
2. Discuss the role of the microbiome in the pathogenesis of Parkinson’s disease, highlighting evidence from animal models to human studies

705: Video Session

Pediatric Hyperkinetic Movement Disorders: Approach to a Child who Moves Too Much
18:00 – 19:30 GMT

In this interactive session, the presenters will demonstrate with illustrative videos the wide phenotypic spectrum of hyperkinetic pediatric movement disorders. The audience will also observe video cases of potentially treatable hyperkinetic pediatric movement disorders that are important not to miss.

Serena Galosi, Italy
Toni Pearson, USA

CSPC Liaisons: Orlando Barsottini, Brazil
Jennifer Friedman, USA

Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Describe the phenotypic spectrum of hyperkinetic movement disorders in children
2. Recognize potentially treatable hyperkinetic pediatric movement disorders
WEDNESDAY, SEPTEMBER 16, 2020

205: Plenary Session

**Digital Health Technologies in Movement Disorders**
12:00 – 14:00 GMT

Chairs: Roongroj Bhidayasiri, Thailand
Christopher Goetz, USA

Digital Health Technologies: The Toolbox in 2020
Walter Maetzler, Germany
Digital Technologies for Diagnosis and Disease Monitoring
Bastiaan Bloem, Netherlands
Digital Health Pathway for Personalized and Integrated Care
Alberto Espay, USA

CSPC Liaison: Roongroj Bhidayasiri, Thailand

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Summarize the digital health technologies available for research and clinical care of movement disorders
2. Discuss opportunities and challenges of digital health technologies for diagnosis and disease monitoring in clinical trials and patients management
3. Discuss the concept of digital health pathway for patient-centered integrated care

206: Plenary Session

**Translational Insights into New Parkinson's Disease-Modifying Therapies**
12:00 – 14:00 GMT

Chairs: Joseph Jankovic, USA
Tiago Outeiro, Germany

Lysosomal Dysfunction in Parkinson’s Disease: From Genetics to the Bedside
Leonidas Stefanis, Greece
The Immune System as a Target for Intervention in Parkinson’s Disease
Malu Tansey, USA
Antibody-Based Therapies: Present and Future
Eliezer Masliah, USA

CSPC Liaison: Tiago Outeiro, Germany

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Discuss the potential of lysosome-targeted therapies in Parkinson’s disease
2. Discuss the role of the immune system as a target for intervention in Parkinson’s disease
3. Summarize the status of antibody-based therapies for Parkinson’s disease

207: Plenary Session

**Controversies in Movement Disorders**
14:30 - 16:30 GMT

Chairs: Tove Henriksen, Denmark
Irene Litvan, USA

Antibodies Panels are Under-Utilized in Movement Disorders Diagnosis (YES)
Bettina Balint, United Kingdom
Antibodies Panels are Under-Utilized in Movement Disorders Diagnosis (NO)
Francisco Cardoso, Brazil
Clinical Judgement vs. A.I. Algorithms: A.I. Will Outperform the Clinical Neurologist in the Near Future (YES)
Roongroj Bhidayasiri, Thailand
Clinical Judgement vs. A.I. Algorithms: A.I. Will Outperform the Clinical Neurologist in the Near Future (NO)
Christopher Goetz, USA

CSPC Liaison: Vincenzo Bonifati, Netherlands

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Debate the advantages and disadvantages of antibodies panels in movement disorders diagnosis
2. Debate whether artificial intelligence will outperform clinical judgement in the near future
**208: Plenary Session**

**Highlights from 2020: Looking Toward 2021**
15:30 – 16:30 GMT

**Chairs:**
- Vincenzo Bonifati, Netherlands
- Claudia Trenkwalder, Germany

**Basic Science: Parkinson’s Disease**
- Ryosuke Takahashi, Japan

**Basic Science: Other Movement Disorders**
- Carolyn Sue, Australia

**Clinical Studies: Parkinson’s Disease**
- Shen Yang Lim, Malaysia

**Clinical Studies: Other Movement Disorders**
- Orlando Barsottini, Brazil

**CSPC Liaisons:**
- Vincenzo Bonifati, Netherlands
- Claudia Trenkwalder, Germany

**Recommended Audience:** Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Critically review high-impact scientific discoveries in the field of movement disorders published in the past year, and important areas of scientific focus for 2021 research
2. Critically review high-impact clinical studies in the field of movement disorders published in the past year, and important ongoing trials with anticipated completion in 2020

**MDS-PAS Regional Assembly**

22:30 – 23:00 GMT

All participants from Pan America are encouraged to attend.
NON-CME EDUCATIONAL ACTIVITIES

SCIENCE OF INDUSTRY SESSION (NON-CME):
These interactive sessions will provide participants with a non-CME educational opportunity to learn about novel therapeutic agents under development by industry. Sessions may incorporate basic scientists or clinicians working in industry, and topics may address the biological rationale or development process for specific therapeutics in development within the field of Movement Disorders.

MONDAY, SEPTEMBER 14, 2020

901 Science of Industry (non-CME)

Antisense Oligonucleotides for Treating Movement Disorders
14:30 - 16:30 GMT

Chairs: Stanley Fahn, USA
Buz Jinnah, USA
Biological Basis
Stefan Pulst, USA
Preclinical Treatment Pipeline
To Be Announced
Current Status of Clinical Development
Lauren Boak, Switzerland

CSPC Liaisons: Wassilios Meissner, France
Tiago Outeiro, Germany

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Discuss the biological basis for using antisense oligonucleotides as treatment for movement disorders
2. Summarize the results of preclinical studies using antisense oligonucleotides for treating movement disorders
3. Discuss the current status of clinical trials using antisense oligonucleotides for treating movement disorders

TUESDAY, SEPTEMBER 15, 2020

902 Science of Industry (non-CME)

Immunotherapy for Proteinopathies
14:30 - 16:30 GMT

Chairs: Wassilios Meissner, France
Tiago Outeiro, Germany

Biological Basis
Andrew Siderowf, USA

Update on Preclinical Studies
Warren Hirst, USA

Current Status of Clinical Development
Wagner Zago, USA

CSPC Liaisons: Wassilios Meissner, France
Tiago Outeiro, Germany

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Discuss the biological basis for immunotherapy in neurological disease
2. Summarize the results of preclinical studies based on immunotherapy strategies for treating movement disorders
3. Summarize the current status of clinical trials based on immunotherapy strategies for treating movement disorders

SPONSORED SYMPOSIA
Join daily at 16:30 GMT for our Sponsored Symposia. These industry-based informational sessions provide attendees with non-CME educational opportunities to learn the latest in therapeutics.

SATURDAY, SEPTEMBER 12
AbbVie
ACADIA Pharmaceuticals, Inc.
Sunovion Pharmaceuticals, Inc.
Zambon

SUNDAY, SEPTEMBER 13
Neurocrine Biosciences, Inc.
Sanofi Genzyme

TUESDAY, SEPTEMBER 15
Teva
FACULTY LISTING

Charles Adler, USA
203

Annu Aggarwal, India
608

Wado Akamatsu, Japan
607

Roy Alcalay, USA
508

Tim Anderson, New Zealand
703

Angelo Antonini, Italy
102

Melissa Armstrong, USA
316

Bettina Balint, Germany
207

Orlando Barsottini, Brazil
208, 310

Kailash Bhatia, United Kingdom
313, 403

Roongroj Bhidayasiri, Thailand
205, 207, 308

Bastiaan Bloem, Netherlands
205, 307

Lauren Boak, Switzerland
901

Vincenzo Bonifati, Netherlands
204, 208

Per Borghammer, Denmark
203, 311

Adam Boxer, USA
312

David Burn, United Kingdom
505

Carlos Henrique Camargo, Brazil
310

Francisco Cardoso, Brazil
103, 201, 207

Miriam Carecchio, Italy
608

Patricia Maria Carvalho Aguiar, Brazil
304

Piu Chan, Peoples Republic of China
604

Shengdi Chen, Peoples Republic of China
101, 405

Alice Chen-Plotkin, USA
405

Carlo Colosimo, Italy
403, 506

Cynthia Comella, USA
402, 510

Antonella Consiglio, Spain
602

Pietro Cortelli, Italy
406

Esther Cubo Delgado, Spain
301

Alain Dagher, Canada
311

Nabila Dahodwala, USA
305

Andres Deik, USA
506

Karl Deisseroth, USA
204

Günther Deuschl, Germany
104, 404

Ivo Dinov, USA
601

John Duda, USA
403, 609

Mark Edwards, United Kingdom
303

Terry Ellis, USA
307, 603

Alberto Espay, USA
205

Stanley Fahn, USA
901

Cristian Falup-Pecurariu, Romania
401

Alfonso Fasano, Canada
301

Hubert Fernandez, USA
309, 702

Joaquim Ferreira, Portugal
306

Brent Fogel, USA
310

Jennifer Friedman, USA
202

Steven Frucht, USA
704

Victor Fung, Australia
103, 202

Serena Galosi, Italy
705

Emilia Gatto, Argentina
509

Oscar Gershanik, Argentina
101, 309

Nir Giladi, Israel
701

Christopher Goetz, USA
205, 207

Jennifer Goldman, USA
307

David Goldstein, USA
406

Pedro Gonzalez-Alegre, USA
507

Elisa Greggio, USA
317

Rita Guerreiro, United Kingdom
316

Mark Guttman, Canada
307

Deborah Hall, USA
702

Mark Hallett, USA
303

Tove Henriksen, Denmark
207, 505

Etienne Hirsch, France
204, 317

Warren Hirst, USA
902

Günter Höglinger, Germany
309

Franziska Hopfner, Germany
313

Michele Hu, United Kingdom
405

Howard Hurtig, USA
302

Valeria Iodice, United Kingdom
406
## FACULTY LISTING

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Priya Jagota</td>
<td>Thailand</td>
<td>603</td>
</tr>
<tr>
<td>Joseph Jankovic</td>
<td>USA</td>
<td>206</td>
</tr>
<tr>
<td>Beomseok Jeon</td>
<td>South Korea</td>
<td>101, 605</td>
</tr>
<tr>
<td>Hyder Jinnah</td>
<td>USA</td>
<td>202, 901</td>
</tr>
<tr>
<td>Kejal Kantarci</td>
<td>USA</td>
<td>316</td>
</tr>
<tr>
<td>Maya Katz</td>
<td>USA</td>
<td>307</td>
</tr>
<tr>
<td>Regina Katzenschlager</td>
<td>Austria</td>
<td>101</td>
</tr>
<tr>
<td>Horacio Kaufmann</td>
<td>USA</td>
<td>102</td>
</tr>
<tr>
<td>Lucy Kaufmann</td>
<td>USA</td>
<td>302</td>
</tr>
<tr>
<td>Han-Joon Kim</td>
<td>South Korea</td>
<td>403</td>
</tr>
<tr>
<td>Asha Kishore</td>
<td>India</td>
<td>704</td>
</tr>
<tr>
<td>Christine Klein</td>
<td>Germany</td>
<td>304, 508</td>
</tr>
<tr>
<td>Thomas Klockgether</td>
<td>Germany</td>
<td>315</td>
</tr>
<tr>
<td>Maja Kojovic</td>
<td>Slovenia</td>
<td>313</td>
</tr>
<tr>
<td>Amanda Krause</td>
<td>South Africa</td>
<td>306</td>
</tr>
<tr>
<td>Daniel Kremens</td>
<td>USA</td>
<td>317</td>
</tr>
<tr>
<td>Andrea Kuehn</td>
<td>Germany</td>
<td>104, 404</td>
</tr>
<tr>
<td>Manju Kurian</td>
<td>United Kingdom</td>
<td>202</td>
</tr>
<tr>
<td>G. Bernhard Landwehrmeyer</td>
<td>Germany</td>
<td>306</td>
</tr>
<tr>
<td>Blair Leavitt</td>
<td>Canada</td>
<td>309</td>
</tr>
<tr>
<td>Jee-Young Lee</td>
<td>South Korea</td>
<td>311</td>
</tr>
<tr>
<td>Virginia Lee</td>
<td>USA</td>
<td>302</td>
</tr>
<tr>
<td>Y. Joyce Liao</td>
<td>USA</td>
<td>703</td>
</tr>
<tr>
<td>Shen-Yang Lim</td>
<td>Malaysia</td>
<td>208</td>
</tr>
<tr>
<td>Patricia Limousin</td>
<td>United Kingdom</td>
<td>104</td>
</tr>
<tr>
<td>Chin-Hsien Lin</td>
<td>Taiwan</td>
<td>304</td>
</tr>
<tr>
<td>Irene Litvan</td>
<td>USA</td>
<td>207</td>
</tr>
<tr>
<td>Stefan Lorenzi</td>
<td>Germany</td>
<td>501</td>
</tr>
<tr>
<td>Pierre-Hervé Luppi</td>
<td>France</td>
<td>308</td>
</tr>
<tr>
<td>Walter Maetzler</td>
<td>Germany</td>
<td>205</td>
</tr>
<tr>
<td>Karen Marder</td>
<td>USA</td>
<td>316</td>
</tr>
<tr>
<td>Connie Marras</td>
<td>Canada</td>
<td>305</td>
</tr>
<tr>
<td>Eliezer Masliah</td>
<td>USA</td>
<td>206</td>
</tr>
<tr>
<td>Wassilios Meissner</td>
<td>France</td>
<td>302, 902</td>
</tr>
<tr>
<td>Marcelo Merello</td>
<td>Argentina</td>
<td>401</td>
</tr>
<tr>
<td>Janis Miyasaki</td>
<td>Canada</td>
<td>501</td>
</tr>
<tr>
<td>Brit Mollenhauer</td>
<td>Germany</td>
<td>203, 405</td>
</tr>
<tr>
<td>Francesca Morgante</td>
<td>United Kingdom</td>
<td>303</td>
</tr>
<tr>
<td>James Morley</td>
<td>USA</td>
<td>401</td>
</tr>
<tr>
<td>Elena Moro</td>
<td>France</td>
<td>301, 404</td>
</tr>
<tr>
<td>Timothy Nicholson</td>
<td>United Kingdom</td>
<td>303</td>
</tr>
<tr>
<td>Alice Nieuwboer</td>
<td>Belgium</td>
<td>101</td>
</tr>
<tr>
<td>Mona Obaid</td>
<td>Saudi Arabia</td>
<td>504</td>
</tr>
<tr>
<td>Jose Obeso</td>
<td>Spain</td>
<td>104</td>
</tr>
<tr>
<td>Njideka Okubadejo</td>
<td>Nigeria</td>
<td>604</td>
</tr>
<tr>
<td>Michael Okun</td>
<td>USA</td>
<td>404</td>
</tr>
<tr>
<td>Avi Orr-Urtreger</td>
<td>Israel</td>
<td>508</td>
</tr>
<tr>
<td>Daniel Otzen</td>
<td>Denmark</td>
<td>317</td>
</tr>
<tr>
<td>Tiago Outeiro</td>
<td>Germany</td>
<td>206, 902</td>
</tr>
<tr>
<td>Martin Paucar Arce</td>
<td>Sweden</td>
<td>304</td>
</tr>
<tr>
<td>Henry Paulson</td>
<td>USA</td>
<td>315</td>
</tr>
<tr>
<td>Toni Pearson</td>
<td>USA</td>
<td>705</td>
</tr>
<tr>
<td>José Luiz Pedroso</td>
<td>Brazil</td>
<td>402</td>
</tr>
<tr>
<td>Marina Picillo</td>
<td>Italy</td>
<td>403</td>
</tr>
<tr>
<td>Werner Poewe</td>
<td>Austria</td>
<td>201</td>
</tr>
<tr>
<td>Marios Politis</td>
<td>United Kingdom</td>
<td>503</td>
</tr>
<tr>
<td>Kathleen Poston</td>
<td>USA</td>
<td>405</td>
</tr>
<tr>
<td>Ron Postuma</td>
<td>Canada</td>
<td>102, 308</td>
</tr>
<tr>
<td>Tamara Pringsheim</td>
<td>Canada</td>
<td>402</td>
</tr>
<tr>
<td>Federica Provini</td>
<td>Italy</td>
<td>308</td>
</tr>
<tr>
<td>Stefan Pulst</td>
<td>USA</td>
<td>901</td>
</tr>
<tr>
<td>Heinz Reichmann</td>
<td>Germany</td>
<td>314</td>
</tr>
<tr>
<td>Mayela Rodriguez Violante</td>
<td>Mexico</td>
<td>202, 504</td>
</tr>
<tr>
<td>James Rowe</td>
<td>United Kingdom</td>
<td>312</td>
</tr>
<tr>
<td>Evzen Ruzicka</td>
<td>Czech Republic</td>
<td>701</td>
</tr>
<tr>
<td>Ryuji Sakakibara</td>
<td>Japan</td>
<td>606</td>
</tr>
<tr>
<td>Paola Sandroni</td>
<td>USA</td>
<td>606</td>
</tr>
<tr>
<td>Rachel Saunders-Pullman</td>
<td>USA</td>
<td>103</td>
</tr>
<tr>
<td>Rodolfo Savica</td>
<td>USA</td>
<td>305</td>
</tr>
</tbody>
</table>
FACULTY LISTING

Filip Scheperjans, Finland
314
Clemens Scherzer, USA
305
Susanne Schneider, Germany
402
Anette Schrag, United Kingdom
102
Klaus Seppi, Austria
503
Tereza Serranova, Czech Republic
303
Aasef Shaikh, USA
313
Huifang Shang, Peoples Republic of China
301
Madeleine Sharp, Canada
401
Hiroshi Shibasaki, Japan
201
Andrew Siderowf, USA
203, 902
Ellen Sidransky, USA
317
Tatyana Simuni, USA
309
Matej Skorvanek, Slovakia
509
Meredith Spindler, USA
604
Maria Stamelou, Greece
312
Ambra Stefani, Austria
308
Leonidas Stefanis, Greece
206
Matthew Stern, USA
101
Beth Stevens, USA
204
A. Jon Stoessl, Canada
203, 311
Antonio Strafella, Canada
311
Indu Subramanian, USA
301
Carolyn Sue, Australia
208, 304, 314
David Sulzer, USA
602
Pille Taba, Estonia
101, 605
Ryosuke Takahashi, Japan
208, 302
Ai Huey Tan, Malaysia
314
Louis Tan, Singapore
102, 313
Eng-King Tan, Singapore
607
Malu Tansey, USA
206
Eduardo Tolosa, Spain
103
Claudia Trenkwelder, Germany
201, 208
Joanne Trinh, Germany
507
Elina Tripoliti, United Kingdom
502
Michelle Troche, USA
502
Yoshikazu Ugawa, Japan
103
Marie Vidailhet, France
510
Jens Volkmann, Germany
104
Ruth Walker, USA
103
Daniel Weintraub, USA
102, 401
Edward Wild, United Kingdom
315
Allison Willis, USA
601
Ruey-Meei Wu, Taiwan
314
Qin Xiao, People’s Republic of China
609
Wagner Zago, USA
902
ACKNOWLEDGEMENTS

The International Congress of Parkinson’s Disease and Movement Disorders Virtual Congress wishes to acknowledge the following commercial supporters:

### DIAMOND LEVEL

- Bial
- **AbbVie**
- **Genentech**
- **Medtronic**
- **Neurocrine Biosciences**
- **Sunovion**

### PLATINUM LEVEL

- **Acadia Pharmaceuticals**
- **ACORDA Therapeutics**
- **Sanofi-Genzyme**
- **Teva**
- **Zambon**

### SILVER LEVEL

- **Allergan**
- **Amneal**
- **Lundbeck**

The MDS Virtual Congress also acknowledges the following sponsors who made their commitments by July 1: Abbott, Adamas Pharmaceuticals, Inc., Boston Scientific, Britannia Pharmaceuticals, ConvaTec, Defeat MSA Alliance, EVER Neuro Pharma GmbH, GE Healthcare Ltd, IPSEN, Kyowa Kirin, Merz Therapeutics, NeuroDerm, PD Neurotechnology, Ltd., Syneric Medical Technologies, Voyager Therapeutics.
Become a Member of MDS

Join over 9,000 movement disorders professionals across the globe in working to disseminate knowledge and promote research to advance the field.

**MDS Members receive the following benefits:**

- **Peer Reviewed Journals:** Movement Disorders and Movement Disorders Clinical Practice
- **Quarterly Newsletter:** Moving Along
- **Reduced Course Registration Fees**
- **Online Resources:** CME activities; streaming content; and a video library with over 2,000 searchable videos

**NON-MEMBER OPPORTUNITIES**

Free One-Year Trial Membership
Open to Eligible Virtual Congress Participants

**ASSOCIATE MEMBERSHIP**

Non-members attending the Virtual Congress have the opportunity to receive membership with MOS absolutely free for a year. Eligible participants will be invited by e-mail to apply for free Associate Membership. Interested individuals are encouraged to apply online within 30 days of contact.

Learn more at www.movementdisorders.org/associate-membership.htm or contact the International Secretariat: MDS International Secretariat; 555 East Wells Street, Suite 1100; Milwaukee, WI 53202 USA; Tel:+ 1 414-276-2145; Fax:+ 1 414-276-3349; E-mail: membership@movementdisorders.org

www.movementdisorders.org/membership
Inbrija
(levodopa inhalation powder)

FOR MORE INFORMATION, VISIT
INBRIJAinfo.com

ACORDA THERAPEUTICS, the stylized ACORDA THERAPEUTICS logo, INBRIJA and the INBRIJA logo are trademarks of Acorda Therapeutics, Inc. ©2020 Acorda Therapeutics, Inc. All rights reserved.
At Adamas our purpose is to make everyday life significantly better for people affected by neurological diseases.

For more information, please visit our website at www.adamaspharma.com.
We have existed since 1924 to give you more and better health. Caring for your life, is more than a mission, it’s our dream. This dream remains as alive today as in the beginning. And we know that the only way to realize it, is by innovating. Innovation is the energy that feeds the dream. That drives us to search for new medicines. And keeps us working around the world. Always caring for your health.
**VERCISE™**
Deep Brain Stimulation Systems

**SIMPLY ADVANCED**

Simple and intuitive controls provide DBS programmers flexibility and options to manage patients’ therapy.*

*One touch buttons make directional programming intuitive and simple.

**Indications for Use:** The Vercise™ Deep Brain Stimulation (DBS) Systems are indicated for use in bilateral stimulation of the subthalamic nucleus (STN) as adjunctive therapies in reducing some of the symptoms of moderate to advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.

**Contraindications, warnings, precautions, side effects:** Vercise DBS Systems, or any of their components, are contraindicated for: Diathermy as either a treatment for a medical condition or as part of a surgical procedure, Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation (TMS) as the safety of these therapies in patients implanted with Vercise DBS Systems has not been established, Magnetic Resonance Imaging (MRI), patients who are unable to operate the system, patients who are poor surgical candidates or who experience unsuccessful test stimulation. Refer to the Instructions for Use provided with Vercise DBS Systems or BostonScientific.com for potential adverse effects, warnings, and precautions prior to using this product.

**Caution:** U.S. federal law restricts this device to sale by or on the order of a physician. All trademarks are the property of their respective owners.

NM-557903-AA  Copyright ©2018 by Boston Scientific Corporation or its affiliates. All rights reserved.
NOW APPROVED

Sunovion Pharmaceuticals Inc. is a proud sponsor of the 2020 MDS Virtual Congress. To learn more about KYNMOBI and to register for product updates, please visit www.KYNMOBI.com.

For support services, call Sunovion Answers at 1-844-596-6624.
Developing non-invasive neuromodulation for Parkinson’s Disease

Our research is advancing our understanding of how Parkinson’s disease alters brain activity and, consequently, how our non-invasive neuromodulation techniques may restore specific brain functions and relieve Parkinson’s disease symptoms.

1https://www.insightec.com/media/21395/erobotineurontinformationprescribenusa.pdf